

Pacira BioSciences Inc (PCRX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/PC38F2DEC391EN.html>

Date: March 2021

Pages: 51

Price: US\$ 125.00 (Single User License)

ID: PC38F2DEC391EN

Abstracts

Pacira BioSciences Inc (PCRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pacira BioSciences Inc (Pacira), formerly Pacira Pharmaceuticals Inc, provides non-opioid pain management and regenerative health solutions. The company develops drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic administered at the time of surgery to control pain and eliminate the use of opioids for acute postsurgical pain. Its other products include iovera, a non-opioid treatment intended to block pain, pain relief and symptoms related with osteoarthritis of the knee; among others. Its products are essentially used by hospitals, doctors and ambulatory surgery centers. The company sells products through co-promotion agreements and supply agreements with other pharmaceutical companies. The company has operations in the US and the UK. Pacira is headquartered in Parsippany, New Jersey, the US.

Pacira BioSciences Inc Key Recent Developments

Mar 09,2021: Pacira BioSciences reports preliminary net product sales of \$36.2 million for February 2021

Mar 03,2021: Pacira BioSciences to Present at the 2021 Barclays Global Healthcare

Conference

Feb 25,2021: Pacira BioSciences reports full-year and fourth quarter 2020 financial results

Feb 25,2021: Pacira Biosciences, to Host Earnings Call

Feb 10,2021: Pacira BioSciences reports preliminary net product sales of \$36.0 million for January 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the

revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Pacira BioSciences Inc - Key Facts
Pacira BioSciences Inc - Key Employees
Pacira BioSciences Inc - Key Employee Biographies
Pacira BioSciences Inc - Major Products and Services
Pacira BioSciences Inc - History
Pacira BioSciences Inc - Company Statement
Pacira BioSciences Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Pacira BioSciences Inc - Business Description
Product Category: Bupivacaine liposome injectable suspension
Performance
Product Category: Exparel
Overview
Performance
Product Category: iovera
Performance
R&D Overview
Pacira BioSciences Inc - Corporate Strategy
Pacira BioSciences Inc - SWOT Analysis
SWOT Analysis - Overview
Pacira BioSciences Inc - Strengths
Pacira BioSciences Inc - Weaknesses
Pacira BioSciences Inc - Opportunities
Pacira BioSciences Inc - Threats
Pacira BioSciences Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios

Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Pacira BioSciences Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 09, 2021: Pacira BioSciences reports preliminary net product sales of \$36.2 million for February 2021

Mar 03, 2021: Pacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference

Feb 25, 2021: Pacira BioSciences reports full-year and fourth quarter 2020 financial results

Feb 25, 2021: Pacira Biosciences, to Host Earnings Call

Feb 10, 2021: Pacira BioSciences reports preliminary net product sales of \$36.0 million for January 2021

Jan 07, 2021: Pacira reports record revenue for 2020 of \$429.6 million

Dec 09, 2020: Pacira BioSciences reports preliminary net product sales of \$38.9 million for November 2020

Nov 11, 2020: Pacira BioSciences reports preliminary net product sales of \$41.7 million for October 2020

Oct 29, 2020: Pacira Biosciences reports third quarter 2020 financial results and business update

Oct 21, 2020: Pacira launches state-of-the-art training center dedicated to advancing best practice regional approaches to manage acute pain

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData

Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Pacira BioSciences Inc, Key Facts
Pacira BioSciences Inc, Key Employees
Pacira BioSciences Inc, Key Employee Biographies
Pacira BioSciences Inc, Major Products and Services
Pacira BioSciences Inc, History
Pacira BioSciences Inc, Other Locations
Pacira BioSciences Inc, Subsidiaries
Pacira BioSciences Inc, Key Competitors
Pacira BioSciences Inc, Ratios based on current share price
Pacira BioSciences Inc, Annual Ratios
Pacira BioSciences Inc, Annual Ratios (Cont...1)
Pacira BioSciences Inc, Annual Ratios (Cont...2)
Pacira BioSciences Inc, Interim Ratios
Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Pacira BioSciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Pacira BioSciences Inc, Performance Chart (2016 - 2020)

Pacira BioSciences Inc, Ratio Charts

Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Pacira BioSciences Inc (PCRX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/PC38F2DEC391EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PC38F2DEC391EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970